drugset / Trial / NCT04562298
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
Phase 1
Terminated
15 enrolled
Shanghai East Hospital
Anhui Provincial Hospital · collabEast Clinical Center of Oncology · collabNanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, single-arm, open-label, single-dose dose finding and extension study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the LCAR-M23 CAR-T cell therapy in subjects with relapsed and refractory epithelial ovarian cancer after prior adequate standard of care.
Timeline
- Start
- 2020-10-21
- Primary completion
- 2022-06-07
- Completion
- 2022-06-07
Outcome
Outcome not reported
Stopped: “Both the sponsors and collaborator are considering terminating the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-M23 | Cell therapy | — | — |